DOD, Spinal Cord Injury Research Program, Translational Research Award | W81XWH 22 SCIRP TRA

FAQs: DoD Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA)

What is the SCIRP Translational Research Award (TRA)?

The SCIRP Translational Research Award (TRA) is a Department of Defense funding opportunity intended to move spinal cord injury (SCI) discoveries beyond the lab or early clinical observations and closer to real-world clinical use. It emphasizes research that bridges the gap between discovery and practical patient impact, such as therapies, devices, diagnostics, healthcare technologies, or practice guidelines.

What is the funding opportunity number for this award?

The funding opportunity number is W81XWH 22 SCIRP TRA.

What does "translational research" mean in this announcement?

In this program, translational research means taking a promising SCI idea and developing it far enough that it can realistically move into clinical application. The expectation is that the work is more advanced than basic science exploration and more actionable than purely observational clinical work, with a clear plan to progress toward adoption in clinical settings.

What kinds of outcomes is the program trying to achieve?

The TRA is designed to accelerate SCI research toward tangible clinical outcomes. The announcement highlights potential endpoints such as a therapy, a medical device, a diagnostic approach, a healthcare technology introduced into clinical care, or an implementable practice guideline that can influence clinical decision-making and standards of care.

What types of projects are specifically highlighted as a fit?

The description highlights projects such as:

• Demonstration studies of pharmaceuticals in preclinical systems
• Demonstration studies of medical devices in preclinical systems
• Clinical research on therapeutics, devices, or clinical practices using human tissues or other human-based resources

Does this program support preclinical research?

Yes. The announcement specifically references preclinical demonstration studies of pharmaceuticals and medical devices, especially when they help build a convincing evidence package that supports progression toward clinical application.

Does this program support clinical research?

Yes. The announcement includes clinical research on therapeutics, devices, or clinical practices, including work that uses human tissues or other human-based resources. It also describes early clinical studies that evaluate feasibility, safety signals, or performance in human-relevant settings.

Is basic science research eligible if it relates to SCI?

The emphasis is on accelerating translation, so projects are expected to be more than basic science exploration alone. Research should show how it will bridge the gap between discovery and practical patient impact, rather than remaining purely exploratory.

Are purely observational clinical studies considered a good fit?

The announcement indicates that projects should be more than purely observational clinical work. Observations can be a starting point, but the proposed work should be positioned to test, develop, or validate something in a way that moves toward clinical application.

Is the program limited to products like drugs and devices?

No. In addition to therapeutics and devices, the program description also includes the clinical introduction of healthcare technologies and practice guidelines, as long as the work is genuinely translational and positioned to affect clinical decision-making.

Does the program require a "bench to bedside" pathway?

No. The program explicitly states that translation is not treated as a one-way pipeline from bench to bedside. It recognizes that clinically driven insights can be just as important as laboratory discoveries and encourages a two-way exchange between basic and clinical science.

Where can research ideas originate for this award?

The program recognizes multiple origins for translational ideas, including laboratory findings, population-based studies, and clinician experience with patients. It also notes that patterns observed in routine care, including anecdotal observations, can serve as a starting point if they are systematically tested.

Who is offering and administering this funding opportunity?

This is a discretionary funding opportunity offered by the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What funding mechanisms are mentioned?

The opportunity lists both grants and cooperative agreements as funding mechanisms. Cooperative agreements can indicate a structure where the funder may have more active programmatic involvement, depending on the project and how it is managed.

What is the activity category for this opportunity?

The activity category is Science and Technology and other Research and Development.

What is the CFDA number associated with this opportunity?

The CFDA number listed is 12.420.

Who is eligible to apply?

Eligibility is listed as unrestricted, meaning it is broadly open to applicants across entity types, subject to any additional eligibility details that may be specified in the full announcement.

How many awards were anticipated?

The opportunity anticipated making about five awards.

When was this opportunity created?

The opportunity was created on March 28, 2022.

What was the original closing date?

The original closing date listed was September 2, 2022.

Is there a maximum award amount (award ceiling) listed?

The summary lists the award ceiling as 0, which typically means the maximum award amount is not provided in that summary field. The maximum would need to be confirmed in the full funding announcement or related program guidance.

What is the central expectation for a strong TRA proposal?

The program is geared toward teams that can present a clear and credible path to clinical application in SCI. A strong proposal is expected to connect preclinical and clinical perspectives and demonstrate how the work will accelerate translation into implementable improvements for patients.